[Adamantiadi-Behçet syndrome: treatment with recombinant leukocytic interferon]. / Sindrom Adamantiadi-Bekhcheta: lechenie rekombinantnym leikotsitarnym interferonom.

AIM: To evaluate efficacy of synthetic leukocytic interferon (SLI) in patients with severe Adamantiadi-Behçet syndrome (ABS). MATERIALS AND METHODS: The trial enrolled 18 patients (11 men and 7 women aged 25 to 43 years) with severe ABS. The duration of the disease ranged from 1 to 12 years. Subcutaneous ABS injections in a dose 5 x 10(6) U/m2 for 8 weeks followed by 3 x 10(6) for 16 weeks. The results were estimated by standard clinical and biochemical indices. RESULTS: All 18 patients responded to the treatment. After the course of treatment 13 patients were in remission for 4-52 months. The rest of the patients were given one more course of treatment.